Primitive neuroectodermal tumor (PNET) as second malignancy after treatment of Hodgkin's disease.
Hodgkin's disease survivors are at an increased risk of developing second malignant neoplasms including secondary bone tumors. Common secondary bone tumors are osteogenic sarcoma and fibrosarcoma. Secondary primitive neuroectodermal tumor is extremely rare in this group. We present below, a rare case of secondary PNET in an 8-year-old child with Hodgkin's disease which developed unusually early outside the radiation portal and discuss potential factors responsible for its causation.
Khadwal
A
A
Division of Pediatric Oncology, Tata Memorial Hospital, Mumbai, India.
Biswas
G
G
Arora
B
B
Kurkure
P A
PA
Deshmukh
C
C
Shetty
V
V
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D001859:Bone Neoplasms; D002648:Child; D003606:Dacarbazine / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D004317:Doxorubicin / Q000627:therapeutic use; D005269:Femur; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D008482:Mediastinum; D016609:Neoplasms, Second Primary; D018242:Neuroectodermal Tumors, Primitive; D014747:Vinblastine / Q000627:therapeutic use
D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin